MADHAVBAUG

What Vaidya Sane Ayurved Laboratories promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q2 FY26

what the last two calls moved 8 tracked 0 delivered 1 missed 7 open
  • GIPSA Approval Status went quiet said Q4 FY25 Promised: within a couple of months max, we should be GIPSA approved Q2 FY26: No mention of GIPSA approval in the provided text.
  • FY26 EBITDA Margin revised up said Q4 FY25 Promised: reach about 16% or so Q2 FY26: Targeting an EBITDA margin of around 17% to 18%
  • FY26 Revenue on track said Q4 FY25 Promised: Rs. 110 to Rs. 120 crore kind of revenue next year Q2 FY26: Expect revenue to cross about INR 115 crores to INR 120 crores

The rest of the ledger

Above is what the last two calls moved. Pro opens all 8 tracked commitments for Vaidya Sane Ayurved Laboratories — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens